Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.

By R. Gardner, David Wu, S. Cherian, Min Fang, L. Hanafi, O. Finney, H. Smithers, M. Jensen, S. Riddell, D. Maloney and 1 more. Blood, 2016

707 citations recorded by the source corpus.

Subfields: Immunology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/be691be459d32b24651bb1a2e01cdd76ee07839f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Dimiter S. Dimitrov
2. T. Fry
3. C. Mackall

In Oncology

1. N. Shah
2. T. Fry

Citations in the corpus

• CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL (2017, positive): “18 Like CD19, CD22 is expressed on most cases of pre-B cell ALL 14,19,20 , and normal tissue expression is restricted to the B cell lineage.”
• Tumor Antigen Escape from CAR T-cell Therapy. (2018, background): “This was observed in 2 pediatric patients with MLL-rearranged ALL treated with CD19 CAR on the SCRI trial (33) and one adult on the CD19 CAR trial at the FHCC (11).”